Small-cell carcinoma

G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Friday, June 4, 2021

We are encouraged by these preliminary results and look forward to clarifying the potential immune enhancing effects of COSELA in the tumor microenvironment.

Key Points: 
  • We are encouraged by these preliminary results and look forward to clarifying the potential immune enhancing effects of COSELA in the tumor microenvironment.
  • ( poster )
    In the United States, approximately 30,000 small cell lung cancer patients are treated annually.
  • SCLC, one of the two main types of lung cancer, accounts for about 10% to 15% of all lung cancers.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Friday, June 4, 2021

The presentation titled Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer will present evidence for the clinical utility of Resolution ctDx Lung in detecting actionable mutations in non-small cell lung cancer (NSCLC) patients.

Key Points: 
  • The presentation titled Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer will present evidence for the clinical utility of Resolution ctDx Lung in detecting actionable mutations in non-small cell lung cancer (NSCLC) patients.
  • Previous findings have supported the clinical utility of the Resolution ctDx Lung for accurately selecting patients for targeted therapies.1 The latest study, involving the largest prospective liquid biopsy cohort (>1,000 patients) with 34 years of survival data, demonstrates that cell-free DNA guided targeted therapies help result in better overall survival.
  • Significantly, the study highlighted important differences between liquid biopsies and tissue testing, including faster turnaround to reporting, while providing the benefits of guided targeted therapy."
  • A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years

Retrieved on: 
Friday, June 4, 2021

These results the first of their kind in Stage III unresectable lung cancer reinforce the long-term benefit of IMFINZI as the established standard of care in this curative-intent setting.

Key Points: 
  • These results the first of their kind in Stage III unresectable lung cancer reinforce the long-term benefit of IMFINZI as the established standard of care in this curative-intent setting.
  • Immune-mediated colitis occurred in 1.6% (31/1889) of patients receiving IMFINZI, including Grade 4 (0.1%) and Grade 3 (0.3%) adverse reactions.
  • IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
  • Perspectives on Treatment Advances For Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer.

Lung Cancer Research Foundation and EGFR Resisters Announce Partnership

Retrieved on: 
Thursday, June 3, 2021

NEW YORK, June 3, 2021 /PRNewswire/ --The Lung Cancer Research Foundation (LCRF) is excited to announce a partnership with leading lung cancer patient advocacy group, the EGFR Resisters.

Key Points: 
  • NEW YORK, June 3, 2021 /PRNewswire/ --The Lung Cancer Research Foundation (LCRF) is excited to announce a partnership with leading lung cancer patient advocacy group, the EGFR Resisters.
  • People with EGFR positive lung cancer represent a significant number of patients diagnosed with non-small cell lung cancer.
  • The goal of the EGFR Resisters is to improve outcomes for people with EGFR positive lung cancer by accelerating research.
  • The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.

Lung Cancer Research Foundation Welcomes New Members of Board of Directors

Retrieved on: 
Wednesday, June 2, 2021

NEW YORK, June 2, 2021 /PRNewswire/ --The Lung Cancer Research Foundation (LCRF) is pleased to welcome two new members of its Board of Directors, Colleen Conner Ziegler and Bruce Dunbar.

Key Points: 
  • NEW YORK, June 2, 2021 /PRNewswire/ --The Lung Cancer Research Foundation (LCRF) is pleased to welcome two new members of its Board of Directors, Colleen Conner Ziegler and Bruce Dunbar.
  • She is a lung cancer survivor and active patient advocate, diagnosed in May 2015 at the age of 58 with Stage IV ALK positive Non-Small Cell Lung Cancer.
  • The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, June 2, 2021

Small cell lung cancer comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the U.S., Dr. Kovach continued.

Key Points: 
  • Small cell lung cancer comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the U.S., Dr. Kovach continued.
  • The median survivalof patients with this especially aggressive type of lung cancer, even with current best therapy, is approximately nine months.
  • Because of such rapid disease progression, the therapeutic benefit of adding LB-100 to the standard treatment may be seenearlyon in this Phase 1b clinical trial.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Wednesday, June 2, 2021

Onco360, the nations largest independent Oncology Pharmacy, has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Onco360, the nations largest independent Oncology Pharmacy, has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
  • Onco360 is excited to be become a specialty pharmacy provider for ALUNBRIG patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • According to the National Cancer Institutes (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths.
  • When considering all subtypes of lung cancer as well as stages of the disease, lung cancer patients have a poor five-year overall survival (OS) of 21.7%.

Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer

Retrieved on: 
Tuesday, June 1, 2021

LUMAKRAS (Sotorasib) is approved for patients with KRAS G12C-mutated locally advanced stage or metastatic Non-Small Cell Lung Cancer (NSCLC).

Key Points: 
  • LUMAKRAS (Sotorasib) is approved for patients with KRAS G12C-mutated locally advanced stage or metastatic Non-Small Cell Lung Cancer (NSCLC).
  • NSCLC accounts for approximately 84 percent of the 2.2 million new lung cancer diagnoses each year worldwide, including approximately 236,000 new cases in the U.S.
  • Approximately 80% of patients are diagnosed with advanced stage or metastatic cancer.
  • Oncocyte launched DetermaRx, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy.

China Nivolumab Market Investigation Report 2021-2025: A Human IgG4 Monoclonal Antibody that Blocks PD-1 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 1, 2021

The "Investigation Report on China's Nivolumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Nivolumab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to this market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020.
  • Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma.
  • 2 Sales of Nivolumab in China, 2018-2020
    2.3 Sales of Nivolumab by Dosage Form in China, 2018-2020
    3 Analysis of Major Nivolumab Manufacturers in China, 2018-2020
    4 Prices of Nivolumab for Different Manufacturers in China, 2020-2021
    5 Prospect of Chinese Nivolumab drug Market, 2021-2025

New Research Shows EarlySign's AI Model More Accurate for Early Diagnosis of Non-small Cell Lung Cancer

Retrieved on: 
Wednesday, May 26, 2021

TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical data solutions for early detection and prevention of high-burden diseases, announced today the publication of new research impacting the early diagnosis of non-small cell lung cancer (NSCLC).

Key Points: 
  • TEL AVIV, Israel, May 26, 2021 /PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical data solutions for early detection and prevention of high-burden diseases, announced today the publication of new research impacting the early diagnosis of non-small cell lung cancer (NSCLC).
  • The peer-reviewed retrospective data study, Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data , was published in the American Thoracic Journal, "American Journal of Respiratory and Critical Care Medicine."
  • With further validation and refinement, this model has the potential to help prevent lung cancer deaths through earlier diagnosis.
  • The machine learning models from EarlySign can help advance lung cancer identification by nine to twelve months which can lead to earlier diagnosis and treatment, when it matters the most."